- BrightGene looks to the West as obesity shot nears China approvalArmed with impressive Phase 3 data, BrightGene is taking its obesity shot to Chinese regulators. It expects trial data in the West to be even stronger, but its search for a partner for ex-China ter…Endpoints · 25d ago↗ source
- Merck scraps a Phase 2 Alzheimer's asset from partner NeuphoriaMerck has axed a Phase 2 trial testing an experimental Alzheimer’s medicine, Endpoints News has learned. The company terminated a mid-stage test of the oral drug candidate MK-1167, a Merck spokes…Endpoints · 26d ago↗ source
- FDA warns Genzyme's Irish site over quality questionsAn FDA warning letter sent late last month to Genzyme's Ireland-based manufacturing site, now owned by Sanofi, raises significant quality- and data-related issues. On data integrity, the warning…